Selleck Chemicals is your Trusted Supplier
for Inhibitors, Antibodies, Proteins, Kits and Reagents

Selleck products have been cited in studies from Nature, Science and Cell.

17 Nobel Prize winners have published 60 papers with Selleck products.
The Nobel Prize

Shimon Sakaguchi, 2025

Nobel Prize in Physiology or Medicine


David Baker, 2024

Nobel Prize in Chemistry


Katalin Karikó, 2023

Nobel Prize in Physiology or Medicine


David Julius, 2021

Nobel Prize in Physiology or Medicine


Michael Houghton, 2020

Nobel Prize in Physiology or Medicine


Charles M. Rice, 2020

Nobel Prize in Physiology or Medicine


William G. Kaelin Jr, 2019

Nobel Prize in Physiology or Medicine


Peter J. Ratcliffe, 2019

Nobel Prize in Physiology or Medicine


Gregg L. Semenza, 2019

Nobel Prize in Physiology or Medicine


James P. Allison, 2018

Nobel Prize in Physiology or Medicine


Michael Rosbash, 2017

Nobel Prize in Physiology or Medicine


Shinya Yamanaka, 2012

Nobel Prize in Physiology or Medicine


Eric Richard Kandel, 2000

Nobel Prize in Physiology or Medicine


Aziz Sancar, 2015

Nobel Prize in Chemistry


Brian K. Kobilka, 2012

Nobel Prize in Chemistry


Robert Lefkowitz, 2012

Nobel Prize in Chemistry


Aaron Ciechanover, 2004

Nobel Prize in Chemistry


Featured Products

MRTX1133


MRTX1133 is a highly selective inhibitor of mutant KRAS G12D and can reversibly binds to the activated and inactivated KRAS G12D mutants and inhibit their activity. The specificity of MRTX1133 to KRAS G12D is more than 1000 times that of wild-type KRAS.

BI-2865


BI-2865 is a none-covalent pan-KRAS Inhibitor. It binds to WT, G12C, G12D, G12V and G13D mutant KRAS with KDs of 6.9, 4.5, 32, 26, 4.3 nM respectively and inhibits the proliferation of G12C, G12D or G12V mutant KRAS expressing BaF3 ce

AZD0095


AZD0095 is a selective and orally active Monocarboxylate transporter 4 (MCT4) inhibitor with IC50 of 1.3 nM and effectively inhibits the tumor growth in NCI-H358 xenografts in combination with Cediranib.

RMC-7977


RMC-7977 is a potent, reversible, tri-complex oral inhibitor that selectively targets active (GTP-bound) forms of KRAS, HRAS, and NRAS, which exhibits broad-spectrum activity against both mutant and wild-type variants (a RASMULTI (ON) inhibitor). It also exhibits significant anti-tumor efficacy in pancreatic ductal adenocarcinoma (PDAC).

HRO761


HRO761 is a potent, selective, allosteric inhibitor of Werner syndrome RecQ helicase (WRN). It binds at the interface of the D1 and D2 helicase domains, locking WRN in an inactive conformation, and demonstrates anti-proliferative effects specifically in microsatellite instability (MSI) cancer cells.

SB431542


SB431542 is a potent and selective inhibitor of ALK5 with IC50 of 94 nM in a cell-free assay, 100-fold more selective for ALK5 than p38 MAPK and other kinases.

SB202190


SB202190 is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1. SB202190 significantly suppresses Erastin‐dependent ferroptosis.

LY294002


LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.

MG132


MG132 ((S,R,S)-(-)-MG132, Z-Leu-D-Leu-Leu-al) is a potent proteasome (ChTL, TL, and PGPH) inhibitor. MG132 also inhibits calpain (IC50=1.2 μM). MG132 can be used to induce animal models of Parkinson’s disease.

IWP-2


IWP-2 is an inhibitor of Wnt processing and secretion with IC50 of 27 nM in a cell-free assay, selective blockage of Porcn-mediated Wnt palmitoylation, does not affect Wnt/β-catenin in general and displays no effect against Wnt-stimulated cellular responses. IWP-2 specifically inhibits CK1δ.

LDN-193189 Dihydrochloride


LDN-193189 (DM3189) 2HCl is a selective BMP signaling inhibitor, inhibits the ALK1, ALK2, ALK3 and ALK6 with IC50s of 0.8 nM, 0.8 nM, 5.3 nM and 16.7 nM in the kinase assay, respectively. LDN-193189 inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50s of 5 nM and 30 nM in C2C12 cells, respectively, exhibits 200-fold selectivity for BMP versus TGF-β.

GW4869


GW4869 (GW69A, GW554869A) is a neutral, noncompetitive inhibitor of sphingomyelinase (SMase) with an IC50 of 1 μM. It is selective for N-SMase, and does not inhibit acid SMase at up to at least 150 μM, also is a commonly used exosome inhibitor.

A-83-01


A-83-01 is a potent inhibitor of TGF-β type I receptor (ALK5-TD) with IC50 of 12 nM. A-83-01 also inhibits the transcription induced by activin/nodal type I receptor (ALK4-TD) and nodal type I receptor (ALK7-TD) with IC50 of 45 nM and 7.5 nM, respectively.Solutions are unstable and should be fresh-prepared.

Gsk484 Hydrochloride


GSK484 HCl, a benzoimidazole derivative, is a selective and reversible inhibitor of peptidylarginine deiminase 4 (PAD4) with IC50 of 50 nM in the absence of Calcium.

MCC950 Sodium


MCC950 Sodium is a potent, selective inhibitor of NLRP3 with IC50 of 7.5 nM in BMDMs; but not the AIM2, NLRC4 or NLRP1 inflammasomes.

S63845


S63845 is a new, selective MCL-1 inhibitor with the Kd value of 0.19 nM and has no discernible binding to the other BCL-2 members, BCL-2 or BCL-XL.

A-485


A-485 is a potent, selective and drug-like p300/CBP catalytic inhibitor with an IC50 of 0.06 μM for p300 HAT. It is selective over BET bromodomain proteins and >150 non-epigenetic targets.

AZD7648


AZD7648 is a potent inhibitor of DNA-PK with an IC50 of 0.6 nM in biochemical assay and more than 100-fold selective against 396 other kinases.

PLX5622


PLX5622 is a highly selective CSF-1R inhibitor (IC50 < 10 nmol/L), showing > 20-fold selectivity over KIT and FLT3.

STM2457


STM2457 is a highly potent and selective first-in-class catalytic inhibitor of RNA Methyltransferase METTL3 with an IC50 of 16.9 nM. STM2457 is highly specific for METTL3 and showed no inhibition of other RNA methyltransferases.
New Products

Anti-mouse CD11c-Invivo


The N418 monoclonal antibody reacts with mouse CD11c, the most widely used defining marker for murine dendritic cells (DCs). CD11c is also known as integrin alpha-X (Itgax) and CD11 antigen-like family member C.

JNJ-9350


JNJ-9350 is a chemical probe that inhibits spermine oxidase (SMOX) with an IC50 of 0.01 μM. This compound also shows inhibitory activity against polyamine oxidase (PAO), exhibiting an IC50 of 0.79 μM. JNJ-9350 has potential applications in cancer research.

VQW-765


VQW-765 (AQW-051) is an orally active agonist targeting the alpha-7 nicotinic acetylcholine receptor (α7-nAChR), exhibiting a pKD of 7.56 for the human recombinant α7-nAChR. This compound demonstrates anxiolytic-like activity in animal models. VQW-765 has potential applications in anxiety disorder and acute performance anxiety studies.

Asundexian


Asundexian (BAY 2433334) is an orally administered inhibitor of coagulation factor XIa (FXIa). It binds reversibly to the FXIa active site with high affinity, blocking its enzymatic function. In buffer systems, asundexian exhibits an IC50 of 1 nM against human FXIa.

STAT3-IN-13


STAT3-IN-13 (compound 6f) is a STAT3 inhibitor. It exhibits anti-proliferative activity and binds to the STAT3 SH2 domain with a KD of 0.46 μM. This compound inhibits STAT3 Y705 phosphorylation and downstream target gene expression. In vitro studies show STAT3-IN-13 induces apoptosis, while in vivo experiments demonstrate its ability to suppress tumor growth and metastasis. STAT3-IN-13 has potential applications in cancer research.

BBO-10203


BBO-10203 inhibits PI3Kα and KRASG12C by covalently binding to Cys242 in the PI3Kα RAS-Binding Domain. It inhibits both GTP-bound and GDP-bound KRASG12C states, with IC50 and EC50 values of 0.031 nM and 0.02 nM respectively. This compound interferes with RAS-PI3Kα interaction, suppressing RAS-dependent PI3Kα activation. It decreases pERK levels, inhibits cell proliferation, and causes G1 phase arrest and apoptosis. BBO-10203 has potential applications in breast cancer, colorectal cancer, and non-small cell lung cancer research.

GE11


GE11 is an active peptide that binds with colloidal drug delivery systems, serving as smart carriers for antitumor drugs in cancer research.

DPhPC


DPhPC is a phosphatidylcholine (PC) derivative employed in the synthesis of bilayer vesicle phospholipids. The DPhPC bilayer membranes exhibit minimal ion leakage in the absence of pores or ion channels, making them suitable for investigating ion channel activity and membrane potential regulation. DPhPC-based nanoliposomes (NTG) enhance nitric oxide (NO) bioavailability and demonstrate anti-inflammatory properties.

CHOP Antibody [C21N8]


CHOP,DDIT3,DDIT3/GADD153/CHOP,GADD153/CHOP

HSL Antibody [M23F5]


Hormone sensitive lipase/HSL,HSL

CA9 Antibody [J19A24]


CA9,Carbonic Anhydrase 9/CA9,Carbonic Anhydrase IX/CA9

Sp7/Osterix Antibody [J12J9]


OSX,Sp7 / Osterix

CD11b + CD11c Antibody [C8C21]


CD11b + CD11c,CD11b/c

VSV-G tag Antibody [N12B16]


VSV Glycoprotein,VSV-G tag

α-adaptin A Antibody [D21J17]


alpha Adaptin,alpha-Adaptin,α-Adaptin 1/2

Phospho-SHP2 (Tyr542) Antibody [J17K6]


Phospho-SHP-2 (Tyr542),SHP2 (phospho Y542)

Phospho-STAT1 (Ser727) Antibody [F23C16]


Phospho-Stat1 (Ser727),STAT1 (phospho S727)

Influenza A Virus M2 Protein Antibody [L21L24]


Influenza A M2,Influenza A Virus M2 Protein

IFN-γ Antibody [A4P20]


IFN-γ,Interferon gamma